Intech Biopharm Corporation (6461.TWO)

26.70 -0.30 (-1.11%) At close: 01:30PM CST

Intech Biopharm Corporation

No. 36, Ruiguang Road
3rd Floor Lane 358 Neihu District
Taipei 114
Taiwan
886 2 7721 8877
https://www.intechbiopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 82

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Wei-Shiu Wu	General Manager	2.91M	N/A	N/A
Mr. Yan-Qin Zhao	Senior Division Head and Chief R&D Officer	2.49M	N/A	N/A
Ms. Chien-Yiu Yang	Finance Division Head	1.42M	N/A	N/A
Hugues Hung	Chief Financial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

Corporate governance

Intech Biopharm Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.